Nektar disclosed Phase 2b data for REZPEG in severe alopecia areata, testing a regulatory T-cell stimulation approach against existing...

Monte Rosa's MRT-8102 shows NLRP3 inflammasome activity normalization in Phase 1 study of 108 obese participants with elevated cardiovascular...

Survodutide delivers 13.1% weight loss in Phase III trial for obesity and type 2 diabetes, with significant glycemic improvements...

Decentralized supply management is breaking traditional cold-chain oversight. Here's what DSM failures cost sites in enrollment ramp and budget...

VCN-01 plus gemcitabine/nab-paclitaxel improved OS in metastatic pancreatic cancer. The VIRAGE Phase 2b design shows what rigorous endpoint selection...

Clinical trials recruit faces barriers when patients lack diagnoses. Diagnostic coverage gaps exclude 25M Americans from research participation.

EP-104GI maintains 64% remission rate at 52 weeks in eosinophilic esophagitis trial, offering a single-procedure alternative to daily therapy.

Phathom opens Phase 3 trial testing vonoprazan for non-erosive GERD as an on-demand treatment, potentially changing how the drug...

Cartesian's Descartes-08 retreatment data shows MG patients can receive repeat doses with sustained response, informing Phase 3 dosing strategy.

Immix's NXC-201 achieves 89% complete response rate in Phase 2 AL amyloidosis trial, with 40 of 45 patients showing...